Who are sirolimus, mycophenolat mofetil, fluvastatin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/sirolimus-mycophenolat-mofetil-fluvastatin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

sirolimus, mycophenolat mofetil, fluvastatin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

sirolimus, mycophenolat mofetil, fluvastatin (sirolimus, mycophenolat mofetil, fluvastatin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Immunosuppressive combination therapy with statin. Area: Immunology, Transplantation, Cardiovascular.

marketed Immunosuppressive combination therapy with statin mTOR, IMPDH, HMG-CoA reductase Immunology, Transplantation, Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

sirolimus, mycophenolat mofetil, fluvastatin (sirolimus, mycophenolat mofetil, fluvastatin) — University Hospital Schleswig-Holstein. This is a triple immunosuppressive and lipid-lowering regimen combining mTOR inhibition, inosine monophosphate dehydrogenase inhibition, and HMG-CoA reductase inhibition.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
sirolimus, mycophenolat mofetil, fluvastatin TARGET	sirolimus, mycophenolat mofetil, fluvastatin	University Hospital Schleswig-Holstein	marketed	Immunosuppressive combination therapy with statin	mTOR, IMPDH, HMG-CoA reductase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Immunosuppressive combination therapy with statin class)

University Hospital Schleswig-Holstein · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). sirolimus, mycophenolat mofetil, fluvastatin — Competitive Intelligence Brief. https://druglandscape.com/ci/sirolimus-mycophenolat-mofetil-fluvastatin. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab